Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025743 | 0.87 | HTR2C (0.32) | ACVR1DPP4CFTR | |
| SCHEMBL10025682 | 0.86 | CFTR (0.33) | DPP4MGLLCFTR | |
| SCHEMBL10025744 | 0.85 | CACNA1I (0.37) | HDAC4HDAC6HDAC1PDE4APDE4B | |
| Hydrochloric Acid SCHEMBL14956523 | 0.84 | CACNA1I (0.38) | HDAC4HDAC6HDAC1PDE4APDE4B | |
| SCHEMBL2858951 | 0.82 | HTR2A (0.32) | DPP4MGLL | |
| SCHEMBL10025558 | 0.81 | DPP4 (0.43) | DPP4MGLLKMT2AALDH1A1 | |
| SCHEMBL31699802 | 0.81 | ALDH1A1 (0.43) | CYP1A2DPP4PDE4AKMT2AALDH1A1 | |
| SCHEMBL14955967 | 0.80 | HTR2A (0.33) | — | |
| SCHEMBL10025712 | 0.79 | SCN9A (0.33) | DPP4 | |
| SCHEMBL10025740 | 0.79 | MGLL (0.31) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-9566277-B2 | Methods of using phthalazinone ketone derivatives | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2017-02-14 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2016-06-02 | — | — | US | disclosed |
| EP-2604610-B1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| US-9273052-B2 | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-03-01 | — | — | US | disclosed |
| EP-2604610-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) | 2013-06-19 | — | — | EP | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-05-23 | — | — | US | disclosed |
| WO-2012019427-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151367-A1 | METHODS OF USING PHTHALAZINONE KETONE DERIVATIVES | PARP1, PARP2, PARP3 | OPRD1 4019/4885ACVR1 2605/4885RXFP1 4738/4885 |
| US-20130131068-A1 | PHTHALAZINONE KETONE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL USE THEREOF | PARP1, PARP2, PARP4 | OPRD1 3710/4885ACVR1 2521/4885RXFP1 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.